Business Context and Reporting Period
Company: Aspen Aerogels, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2022
Event: Grant of Performance-Based Restricted Stock to senior officers and executives.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on equity compensation arrangements.
Material Changes
On June 2, 2022, the Board of Directors granted 53,590 shares of restricted common stock to each of the following seven executives under the 2014 Employee, Director and Consultant Equity Incentive Plan:
- Kelley W. Conte (SVP, Human Resources)
- George L. Gould (Chief Technology Officer)
- Virginia H. Johnson (Chief Legal Officer, General Counsel)
- Gregg R. Landes (SVP, Operations and Strategic Development)
- Ricardo C. Rodriguez (SVP, Chief Financial Officer)
- Keith Schilling (SVP, Technology)
- Corby Whitaker (SVP, Sales and Marketing)
Guidance, Outlook, and Terms of Award
The awards are subject to both time and performance vesting conditions over a maximum five-year period. Vesting requires the satisfaction of specific share price hurdles based on a 30-day volume weighted average price (VWAP) maintained for 60 days.
| Tranche | Weight | Share Price Hurdle |
|---|---|---|
| Tranche 1 | 34% | $43.33 |
| Tranche 2 | 33% | $64.99 |
| Tranche 3 | 33% | $86.65 |
Change of Control Provisions: In the event of a sale, unearned tranches may be partially earned based on a formula comparing the sale price to a base of $18.66. Earned shares remain subject to time vesting unless the successor company does not assume the agreement, in which case they vest immediately.
Termination Provisions: Termination for Cause or resignation without Good Reason results in immediate forfeiture of all unvested shares. Termination without Cause or resignation for Good Reason allows for pro-rata earning of the next unearned tranche based on the stock price at the termination date.
Investor Verification Checklist
- Verify the current trading price of ASPN relative to the $43.33, $64.99, and $86.65 performance hurdles to assess vesting probability.
- Review the 2014 Equity Incentive Plan for total share availability and dilution impact.
- Monitor future 8-K filings for any amendments to the vesting schedule or performance metrics.
- Check subsequent quarterly reports (10-Q) for the actual expense recognition related to these grants.